WO2018223923A1 - Utilisation d'un anticorps pd-1 combiné avec un ligand vegf ou un inhibiteur du récepteur vegf dans la préparation d'un médicament pour le traitement d'une tumeur - Google Patents

Utilisation d'un anticorps pd-1 combiné avec un ligand vegf ou un inhibiteur du récepteur vegf dans la préparation d'un médicament pour le traitement d'une tumeur Download PDF

Info

Publication number
WO2018223923A1
WO2018223923A1 PCT/CN2018/089763 CN2018089763W WO2018223923A1 WO 2018223923 A1 WO2018223923 A1 WO 2018223923A1 CN 2018089763 W CN2018089763 W CN 2018089763W WO 2018223923 A1 WO2018223923 A1 WO 2018223923A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
antibody
tumor
seq
group
Prior art date
Application number
PCT/CN2018/089763
Other languages
English (en)
Chinese (zh)
Inventor
马晨
曹国庆
张蕾
杨昌永
张连山
Original Assignee
江苏恒瑞医药股份有限公司
上海恒瑞医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏恒瑞医药股份有限公司, 上海恒瑞医药有限公司 filed Critical 江苏恒瑞医药股份有限公司
Priority to CN201880004442.XA priority Critical patent/CN109963592B/zh
Publication of WO2018223923A1 publication Critical patent/WO2018223923A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention belongs to the field of medicine and relates to the use of a PD-1 antibody in combination with a VEGF ligand inhibitor or a VEGF receptor inhibitor in the preparation of a medicament for treating tumor.
  • Tumor immunotherapy is a long-term hot spot in the field of cancer therapy, in which T cell tumor immunotherapy is at its core.
  • Tumor immunotherapy is a way to fully utilize and mobilize killer T cells in tumor patients and kill tumors. It may be the most effective and safest way to treat tumors.
  • tumor escape is a huge obstacle to tumor immunotherapy.
  • Tumor cells use their own inhibition of the immune system to promote rapid tumor growth. There is an extremely complex relationship between the immune escape mechanism of tumors and the body's immune response to tumors.
  • Early tumor-specific killer T cells in tumor immunotherapy have biological activity, but they lose their killing function at the late stage of tumor growth. Therefore, tumor immunotherapy is to maximize the patient's own immune system response to the tumor. It not only activates the original immune system response in the body, but also maintains the duration of the immune system response and the intensity of the response. key.
  • PD-1 belongs to the CD28 family and has 23% amino acid homology with cytotoxic T Iymphocyte antigen 4 (CTLA-4), but its expression Unlike CTLA, it is mainly expressed on activated T cells, B cells and myeloid cells.
  • CTLA-4 cytotoxic T Iymphocyte antigen 4
  • PD-1 has two ligands, PD-L1 and PD-L2.
  • PD-L1 is mainly expressed on T cells, B cells, macrophages, and dendritic cells (DCs), and expression on cells after activation can be up-regulated.
  • the new study found that high PD-L1 protein expression was detected in human tumor tissues such as breast cancer, lung cancer, gastric cancer, colon cancer, kidney cancer, and melanoma, and the expression level of PD-L1 was closely related to the clinical and prognosis of patients. .
  • PD-1 and its ligand PD-L1 inhibited the activity of T lymphocytes, and binding of PD-1 to PD-L1 resulted in apoptosis and depletion of activated immune cells.
  • PD-L1 plays a role in suppressing T cell proliferation by the second signaling pathway, blocking the binding between PD-L1/PD-1 has become a very promising emerging target in the field of tumor immunotherapy. Meta-analysis shows human PD.
  • VEGF monoclonal antibody can be combined with anti-PD-1 antibody for immunotherapy ([J]. Clinical & Experimental Immunology, 2013, 172(3): 500-506); VEGF inhibits DC maturation, leading to immunosuppression ([J]. Current treatment options in oncology, 2014, 15(1): 137-146).
  • Nivolumab is used in combination with Suntinib or Pazopanib for the treatment of metastatic renal cell carcinoma (mRCC). Good results are shown (ASCO meeting, (2014): 5010-5010); clinical results of Pembrolizumab in combination with bevacizumab for the treatment of recurrent gliomas show therapeutic efficacy and good tolerance (ASCO meeting, (2016) :2041-2041), but Blumenthal et al. reported that clinical studies of Pembrolizumab in combination with bevacizumab for progressive primary brain tumors have shown that the combination is ineffective.
  • WO2013181452 discloses the use of a PD-1 antagonist, oxaliplatin, folinic acid, 5-FU in combination with or without bevacizumab to treat tumors;
  • WO2016100561 discloses a PD-1 antibody for glioma Uses;
  • WO2016170039, WO2016170040 disclose the use of bevacizumab in combination with a PD-1/PD-L1 antibody for cancer and mediating an immune response.
  • Patent application WO2017054646A provides a novel PD-1 antibody having high affinity, high selectivity and high biological activity, comprising:
  • An antibody light chain variable region comprising at least one LCDR selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6;
  • An antibody heavy chain variable region comprising at least one HCDR selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3.
  • the article "Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors” disclosed the results of the phase I clinical trial of the PD-1 antibody in the treatment of solid tumor patients, and the results showed that A variety of tumors have inhibitory effects, but about 79.3% of the subjects have symptoms of reactive capillary hemangioma.
  • Bevacizumab Is a VEGF inhibitor marketed in the United States on February 26, 2004, for treating various tumors such as lung cancer, ovarian cancer, etc.
  • WO9845331 discloses the sequence and preparation method thereof, and the present invention provides the PD-1 single described in the patent application WO2017054646A.
  • Use of an anti-antigen or antigen-binding fragment thereof in combination with a VEGF receptor inhibitor or a VEGF ligand inhibitor for the preparation of a medicament for treating a tumor.
  • the technical problem to be solved by the present invention is to provide a use of a PD-1 antibody or antigen-binding fragment thereof in combination with a VEGF receptor inhibitor or a VEGF ligand inhibitor for the preparation of a medicament for treating tumors.
  • the PD-1 antibody comprises:
  • An antibody light chain variable region comprising at least one LCDR selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6;
  • An antibody heavy chain variable region comprising at least one HCDR selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3;
  • the VEGF receptor inhibitor is selected from the group consisting of pegaptanib sodium, vandetanib, sorafenib, axitinib, cabozantinib, punatinib, nidanib, regolfinib, Sunitinib, pazopanib, Puquitinib, Rebastinib, Lucitanib hydrochloride, Necuparanib, Ningetinib, Altiratinib.
  • the antibody light chain variable region comprises an LCDR1 as shown in SEQ ID NO: 4, an LCDR2 as shown in SEQ ID NO: 5, and a SEQ ID NO: 6
  • the antibody heavy chain variable region comprises the HCDR 1 as shown in SEQ ID NO: 1, the HCDR 2 as shown in SEQ ID NO: 2, and the HCDR3 as shown in SEQ ID NO: 3.
  • the PD-1 antibody or antigen-binding fragment thereof of the invention is a humanized antibody or a fragment thereof.
  • the humanized antibody light chain sequence of the PD-1 antibody or antigen-binding fragment thereof of the invention is the sequence set forth in SEQ ID NO: 8 or a variant thereof;
  • the variant preferably has an amino acid change of 0-10 in the light chain variable region; more preferably an amino acid change of A43S.
  • the humanized antibody light chain sequence of the PD-1 antibody or antigen-binding fragment thereof of the present invention is the sequence shown in SEQ ID NO: 7 or a variant thereof;
  • the body preferably has an amino acid change of 0-10 in the heavy chain variable region; more preferably an amino acid change of G44R.
  • the humanized antibody light chain sequence is the sequence set forth in SEQ ID NO: 8
  • the heavy chain sequence is the sequence set forth in SEQ ID NO: 7.
  • sequences of the aforementioned humanized antibody heavy and light chains are as follows:
  • a PD-1 antibody or antigen-binding fragment thereof in combination with a VEGF ligand inhibitor or a VEGF receptor inhibitor for the preparation of a medicament for treating a tumor
  • the VEGF ligand inhibitor is selected from the group consisting of Bevacizumab, Removumab, Ranibizumab, Abbotsep, Composip, Abicipar pegol, Brolucizumab, LMG-324, Nesvacumab, Sevacizumab, Tanibirumab, Navicixizumab, RG-7716, LHA- 510, OPT-302, TK-001, GZ-402663, VGX-100, PG-545, BI-836880, GNR-011, BR-55, OTSGC-A24, PAN-90806, AVA-101, ODM-203, TAS-115, X-82, MP-0250, Sitravatinib, 4SC-203, AL-2846,
  • the PD-1 antibody or antigen-binding fragment thereof and the VEGF receptor inhibitor or VEGF ligand inhibitor have synergistic pharmacodynamic effects for treating tumors; preferably, the humanized PD-1 antibody Or the antigen-binding fragment thereof and the VEGF receptor inhibitor or VEGF ligand inhibitor have synergistic pharmacodynamic effects for treating tumors; more preferably, the light chain sequence as shown in SEQ ID NO: 8 and SEQ ID NO:
  • the humanized PD-1 antibody or antigen-binding fragment thereof of the heavy chain sequence shown in Figure 7 has a synergistic pharmacological effect on tumor treatment with a VEGF receptor inhibitor or a VEGF ligand inhibitor.
  • a method of treating a tumor comprising administering to a patient a PD-1 antibody or antigen-binding fragment thereof and a VEGF receptor inhibitor or a VEGF ligand inhibitor, wherein the VEGF receptor inhibitor is selected From pegaptanib sodium, vandetanib, sorafenib, axitinib, cabozantinib, pentatinib, nidanib, regorafenib, sunitinib, pazodab Ni, Puquitinib, Rebastinib, Lucitanib hydrochloride, Necuparanib, Ningetinib, Altiratinib.
  • the tumor is selected from the group consisting of breast cancer, lung cancer, gastric cancer, intestinal cancer, renal cancer, melanoma, leukemia, lymphoma, myeloma, esophageal cancer, liver cancer, biliary tract cancer, pancreatic cancer, head and neck cancer, prostate cancer , ovarian cancer, cervical cancer, endometrial cancer, osteosarcoma, soft tissue sarcoma, neuroblastoma, brain tumor, endocrine organ tumor, bladder cancer, skin cancer, nasopharyngeal carcinoma, rhabdomyosarcoma; preferably breast cancer, lung cancer, Gastric cancer, intestinal cancer, kidney cancer, melanoma, pancreatic cancer, cervical cancer, liver cancer, leukemia, ovarian cancer, lymphoma, brain tumor, esophageal cancer; most preferred lung cancer, gastric cancer, colon cancer, liver cancer, esophageal cancer, lymphoma , kidney cancer, melanoma, cervical
  • the lung cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, preferably non-small cell lung cancer; and the intestinal cancer is selected from the group consisting of small intestine cancer, colon cancer, rectal cancer, colorectal cancer, preferably colon cancer, rectal cancer, and knot.
  • Rectal cancer; the lymphoma is selected from Hodgkin's lymphoma, non-Hodgkin's lymphoma, preferably Hodgkin's lymphoma.
  • the brain tumor is selected from the group consisting of a neuroepithelial tissue tumor, a cranial nerve and a spinal cord nerve tumor, and a meningeal tissue tumor;
  • the neuroepithelial tissue tumor is selected from the group consisting of astrocytoma, anaplastic astrocytoma, glioblastoma.
  • hair cell astrocytoma hair cell astrocytoma, pleomorphic yellow astrocytoma, subependymal giant cell astrocytoma, oligodendroglioma, ependymoma, mixed glioma, choroid plexus Tumors, pineal somatic tumors, embryonic tumors, most preferably astrocytoma, anaplastic astrocytoma, glioblastoma.
  • the above tumor is mediated and/or expressed by PD-1 to express PD-L1.
  • a VEGF receptor inhibitor or a VEGF ligand inhibitor in a weight ratio ranging from 0.01 to 100, selected from 5:1, 3 : 1, 5: 2, 5: 3, 2: 1, 2: 3, 3: 2, 4: 3, 5: 4, 1:1, 5: 6, 4: 5, 3: 4, 3: 5 , 1:2, 2:5, 1:3, 3:10, 4:15, 1:4, 1:5, 1:6, 2:9, 2:15, 1:10, 2:25, 3 :8; preferably 5:3, 4:3, 5:4, 1:1, 3:4, 2:3, 3:5, 1:2, 2:5, 1:3, 3:10, 1: 4, 2:9, 1:5, 1:10, 2:15, 3:8.
  • the ratio by weight of the above PD-1 antibody or antigen-binding fragment thereof to a VEGF receptor inhibitor or a VEGF ligand inhibitor is preferably in a ratio by weight of a PD-1 antibody or an antigen-binding fragment thereof to a VEGF ligand inhibitor.
  • the range more preferably, is the range of weight ratios from the combination of the PD-1 antibody or antigen-binding fragment thereof with bevacizumab or remolozumab.
  • the dose of the PD-1 antibody or antigen-binding fragment thereof is selected from the group consisting of 0.1-100 mg/kg, preferably 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 2.5 mg/kg, 3 mg.
  • the dose is selected from the group consisting of 0.1-100 mg/kg, preferably 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 2.5 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 7.5 mg.
  • the dose of Remoluzumab is selected from 0.1-100 mg/kg, preferably 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 2.5 mg/ Kg, 3mg/kg, 4mg/kg, 5mg/kg, 6mg/kg, 7mg/kg, 7.5mg/kg, 8mg/kg, 9mg/kg, 10mg/kg, 12mg/kg, 12.5mg/kg, 15mg/ Kg, 18 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, most preferably 5 mg/kg, 6 mg/kg, 8 mg/kg, 10 mg/kg, 12.5mg/kg, 12mg/kg, 15mg/ Kg, 18 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, most preferably 5 mg/kg, 6 mg/kg, 8 mg/kg, 10 mg/kg, 12.5mg/kg, 12mg/kg, 15mg/ Kg, 18 mg/kg, 20 mg/kg
  • the dose of the PD-1 antibody or antigen-binding fragment thereof of the present invention is selected from the group consisting of 1-2000 mg, preferably 25 mg, 40 mg, 50 mg, 60 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 400 mg, 500 mg, 750 mg, 800 mg, 1000 mg, most preferably 40 mg, 60 mg, 100 mg, 200 mg, 400 mg.
  • the above PD-1 antibody or antigen-binding fragment thereof is provided in combination with a VEGF receptor inhibitor or a VEGF ligand inhibitor as a medicament for treating a tumor
  • a VEGF receptor inhibitor is selected from the group consisting of pegaptanib sodium, Vandetanib, sorafenib, axitinib, cabotinib, pentatinib, nidanib, regorafenib, sunitinib, pazopanib, Puquitinib, Rebastinib, Lucitanib Hydrochloride, Necuparanib, Ningetinib, Altiratinib.
  • the combined modes of administration of the present invention are selected from the group consisting of simultaneous administration, independent formulation and co-administration or independent formulation and sequential administration.
  • the administration route of the PD-1 antibody or antigen-binding fragment thereof, bevacizumab or remoluzumab according to the present invention is preferably a parenteral administration route, more preferably intravenous injection, intramuscular injection or subcutaneous injection.
  • the present invention further relates to the use of the above PD-1 antibody or antigen-binding fragment thereof in combination with a VEGF receptor inhibitor or a VEGF ligand inhibitor for the preparation of a medicament for treating a tumor, wherein administration of the PD-1 antibody or antigen-binding fragment thereof Frequency is once a day, twice a week, three times a week, once a week, once every two weeks, once every three weeks, once a month, once in February, once in March, once in June, preferably once every two weeks, once every three weeks, one time Once a month, once a month; VEGF receptor inhibitors or VEGF ligand inhibitors are administered once a day, twice a day, three times a day, twice a week, three times a week, once a week, once every two weeks, Once every three weeks, once a month, once in February, once in March, once in June, preferably once a day, once every two weeks, once every three weeks, once a month.
  • the PD-1 antibody or antigen-binding fragment thereof of the present invention has synergistic pharmacological effects in combination with bevacizumab or remolozumab.
  • the present invention also provides a method of reducing an adverse reaction caused by an anti-PD-1 antibody comprising using an anti-PD-1 antibody in combination with a VEGF receptor inhibitor or a VEGF ligand inhibitor.
  • the adverse reaction is a vascular-related adverse reaction, such as a capillary hemangioma.
  • the invention further provides a pharmaceutical composition
  • a pharmaceutical composition comprising an effective amount of a PD-1 antibody or antigen-binding fragment thereof, a VEGF receptor inhibitor or a VEGF ligand inhibitor, and a pharmaceutically acceptable excipient according to the invention , a dilution or carrier, wherein the VEGF receptor inhibitor is selected from the group consisting of pegaptanib sodium, vandetanib, sorafenib, axitinib, cabozantinib, punatinib, nidanib , regomafenib, sunitinib, pazopanib, Puquitinib, Rebastinib, Lucitanib hydrochloride, Necuparanib, Ningetinib, Altiratinib.
  • Combining the anti-PD-1 antibody of the present invention with a VEGF receptor inhibitor or a VEGF ligand inhibitor can not only synergistically enhance the anti-tumor effect, but also reduce or eliminate capillaries caused by anti-PD-1 antibodies Adverse reactions such as tumors.
  • Figure 1 Effect of bevacizumab and PD-1 antibody A alone or in combination on human malignant glioma U-87MG mouse xenografts
  • Figure 3 Effect of bevacizumab and PD-1 antibody A alone or in combination on tumor weight in human malignant glioma U-87MG mice
  • Figure 4 Effect of bevacizumab and PD-1 antibody A alone or in combination on body weight of human malignant glioma U-87MG mice
  • the antibody of the present invention refers to an immunoglobulin, which is a tetrapeptide chain structure in which two identical heavy chains and two identical light chains are linked by interchain disulfide bonds.
  • the immunoglobulin heavy chain constant region has different amino acid composition and arrangement order, so its antigenicity is also different. Accordingly, immunoglobulins can be classified into five classes, or isoforms of immunoglobulins, namely IgM, IgD, IgG, IgA and IgE, the corresponding heavy chains of which are ⁇ chain, ⁇ chain ⁇ , ⁇ , respectively. Chain, ⁇ chain.
  • IgG can be classified into IgG1, IgG2, IgG3, and IgG4.
  • Light chains are classified as either a kappa chain or a lambda chain by the constant region.
  • Each of the five types of Ig may have a kappa chain or a lambda chain.
  • the antibody light chain variable region of the present invention may further comprise a light chain constant region comprising a human or murine kappa, lambda chain or a variant thereof.
  • the antibody heavy chain variable region of the present invention may further comprise a heavy chain constant region comprising human or murine IgG1, 2, 3, 4 or a variant thereof.
  • variable region The sequence of about 110 amino acids near the N-terminus of the antibody heavy and light chains varies greatly, being the variable region (V region); the remaining amino acid sequence near the C-terminus is relatively stable and is a constant region (C region).
  • the variable region includes three hypervariable regions (HVR) and four relatively conserved framework regions (FR). The three hypervariable regions determine the specificity of the antibody, also known as the complementarity determining region (CDR).
  • Each of the light chain variable region (LCVR) and the heavy chain variable region (HCVR) consists of three CDR regions and four FR regions, and the order from the amino terminus to the carboxy terminus is: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • the three CDR regions of the light chain refer to LCDR1, LCDR2, and LCDR3; the three CDR regions of the heavy chain refer to HCDR1, HCDR2, and HCDR3.
  • the CDR amino acid residues of the LCVR region and the HCVR region of the antibody or antigen-binding fragment of the invention conform to the known Kabat numbering rules (LCDR1-3, HCDE2-3) in number and position, or to the kabat and chothia numbering rules ( HCDR1).
  • humanized antibody also known as CDR-grafted antibody, refers to the transplantation of mouse CDR sequences into human antibody variable region frameworks, ie different types of human germline An antibody produced in an antibody framework sequence. It is possible to overcome the strong antibody variable antibody response induced by chimeric antibodies by carrying a large amount of mouse protein components.
  • framework sequences can be obtained from public DNA databases including germline antibody gene sequences or published references.
  • the germline DNA sequences of human heavy and light chain variable region genes can be found in the "VBase" human germline sequence database (available on the Internet at www.mrccpe.com.ac.uk/vbase), as well as in Kabat, EA, etc.
  • the CDR sequence of said PD-1 humanized antibody mouse is selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6.
  • the "antigen-binding fragment” as used in the present invention refers to a Fab fragment having antigen-binding activity, a Fab' fragment, an F(ab')2 fragment, and an Fv fragment sFv fragment which binds to human PD-1;
  • the antibody is selected from one or more of the CDR regions of SEQ ID NO: 1 to SEQ ID NO: 6.
  • the Fv fragment contains the antibody heavy chain variable region and the light chain variable region, but has no constant region and has the smallest antibody fragment of the entire antigen binding site.
  • Fv antibodies also comprise a polypeptide linker between the VH and VL domains and are capable of forming the desired structure for antigen binding.
  • the two antibody variable regions can also be joined by a different linker into a single polypeptide chain, referred to as a single chain antibody or a single chain Fv (sFv).
  • binding to PD-1 refers to the ability to interact with human PD-1.
  • antigen binding site refers to a three-dimensional spatial site that is discrete on an antigen and is recognized by an antibody or antigen-binding fragment of the present invention.
  • administering when applied to an animal, human, experimental subject, cell, tissue, organ or biological fluid, refers to an exogenous drug, therapeutic agent, diagnostic agent or composition and animal, human, subject Contact of the test subject, cell, tissue, organ or biological fluid.
  • administering can refer to, for example, therapeutic, pharmacokinetic, diagnostic, research, and experimental methods.
  • Treatment of the cells includes contact of the reagents with the cells, and contact of the reagents with the fluid, wherein the fluids are in contact with the cells.
  • administeristering and “treating” also means treating, for example, cells in vitro and ex vivo by reagents, diagnostics, binding compositions, or by another cell.
  • Treatment when applied to a human, veterinary or research subject, refers to therapeutic treatment, prophylactic or preventive measures, research and diagnostic applications.
  • Treatment means administering to a patient a therapeutic agent for internal or external use, such as a composition comprising any of the binding compounds of the present invention, the patient having one or more symptoms of the disease, and the therapeutic agent is known to have Therapeutic effect.
  • a therapeutic agent is administered in a subject or population to be treated to effectively alleviate the symptoms of one or more diseases, whether by inducing such symptoms to degenerate or inhibiting the progression of such symptoms to any degree of clinical right measurement.
  • the amount of therapeutic agent also referred to as "therapeutically effective amount” effective to alleviate the symptoms of any particular disease can vary depending on a variety of factors, such as the patient's disease state, age and weight, and the ability of the drug to produce a desired effect in the patient.
  • Whether the symptoms of the disease have been alleviated can be assessed by any clinical test method commonly used by a physician or other professional health care provider to assess the severity or progression of the condition.
  • Embodiments of the invention e.g., methods of treatment or preparations
  • an "effective amount” includes an amount sufficient to ameliorate or prevent a symptom or condition of a medical condition.
  • An effective amount also means an amount sufficient to allow or facilitate the diagnosis.
  • An effective amount for a particular patient or veterinary subject can vary depending on factors such as the condition to be treated, the overall health of the patient, the route and dosage of the method of administration, and the severity of the side effects.
  • An effective amount can be the maximum dose or dosing regimen that avoids significant side effects or toxic effects.
  • the expression "cell”, “cell line” and “cell culture” are used interchangeably and all such names include progeny.
  • the words “transformants” and “transformed cells” include primary test cells and cultures derived therefrom, regardless of the number of transfers. It should also be understood that all offspring may not be exactly identical in terms of DNA content due to intentional or unintentional mutations. Mutant progeny having the same function or biological activity as screened for in the originally transformed cell are included. In the case of a different name, it is clearly visible from the context.
  • the term "synergistic pharmacodynamic effect” includes pharmacodynamic additive action, pharmacodynamic enhancing effect, and pharmacodynamic sensitizing effect, and the “synergistic pharmacodynamic effect” of the present invention includes, but is not limited to, reducing the use of the PD-1 antibody of the present invention alone.
  • VEGF receptor inhibitor or VEGF ligand inhibitor reducing the use of the PD-1 antibody or antigen-binding fragment thereof, VEGF receptor inhibitor or VEGF ligand of the present invention alone
  • the dose at the time of the inhibitor reduces the adverse reaction when the PD-1 antibody or antigen-binding fragment thereof, the VEGF receptor inhibitor or the VEGF ligand inhibitor of the present invention is used alone, and the combination of the two is used to enhance the VEGF when used alone.
  • pharmaceutical composition means a mixture comprising one or more of the compounds described herein, or a physiologically/pharmaceutically acceptable salt or prodrug thereof, and other chemical components, as well as other components such as physiological/pharmaceutically acceptable Carrier and excipients.
  • the purpose of the pharmaceutical composition is to promote the administration of the organism, which facilitates the absorption of the active ingredient and thereby exerts biological activity.
  • the PD-1 antibody or antigen-binding fragment thereof of the invention and the VEGF receptor inhibitor or VEGF ligand inhibitor composition can effectively solve the tumor heterogeneity, play a significant role in inhibiting tumor cells, and effectively inhibit the proliferation and migration of tumor cells or Invasion.
  • Example 1 Therapeutic effect of the PD-1 antibody or antigen-binding fragment thereof of the present invention combined with bevacizumab on subcutaneous xenograft of human malignant glioma U-87MG mice
  • PD-1 antibody A humanized PD-1 antibody consisting of the light chain as shown in SEQ ID NO: 8 and the heavy chain as shown in SEQ ID NO: 7 of the present invention, defined as PD- 1 Antibody A, which is a PD-1 antibody in WO2017054646A), bevacizumab (prepared according to the method described in WO9845331).
  • NOD/SCID female mice were purchased from Cavans (batch number: 201703849), certificate number: SCXK (Su) 2016-0010, 4-6 weeks old at the time of purchase, body weight about 19g, 5/cage rearing, 12/ 12 hours light / dark cycle adjustment, temperature 23 ⁇ 1 ° C constant temperature, humidity 50 ⁇ 60%, free to eat water.
  • PD-1 antibody A was diluted to 20 mg/mL in PBS under sterile conditions, and dispensed into 10 tubes; bevacizumab was opened and then aseptically dispensed into 4 tubes.
  • the above-packed antibody 1 tube was diluted to 0.63 mg/mL with PBS under aseptic conditions, and dispensed into 2.4 mL/tube, a total of 10 tubes, and stored at 4 ° C, and 1 tube was taken for each injection.
  • the PBMCs used in the examples were extracted from fresh blood of two volunteers.
  • the extraction method was as follows:
  • centrifugation at 1200g for 10 minutes at room temperature, centrifugation can lead to the precipitation of red blood cells and multinucleated white blood cells, while forming a layer of mononuclear lymphocytes on the separation solution 1077;
  • lymphocyte layer and the lower half of the separation solution 1077 are transferred to another centrifuge tube. Add an equal volume of PBS and centrifuge at room temperature for 300 minutes at room temperature for 8 minutes;
  • CD3 antibody (40 ng/mL) diluted with PBS was added to a 6-well cell culture plate, 1 mL/well, and incubated at 37 ° C for one hour;
  • mice 100 ⁇ L of U-87MG cells (1.5 ⁇ 10 6 cells/mouse) were inoculated subcutaneously into the right flank of NOD/SCID mice, and after 10 days, the animals with excessive or too small tumor volume were removed, with an average tumor volume of about 65 mm 3 .
  • the mice were randomly divided into 4 groups: vehicle control group, bevacizumab 3 mg/kg single use group, PD-1 antibody A 3 mg/kg single use group and bevacizumab 3 mg/kg+PD-1 antibody. A 3 mg/kg combination group. 9 in each group, the day of the group is recorded as the 0th day.
  • PBMCs of two volunteers stimulated with CD3 antibody were mixed in a 1:1 ratio on the day of grouping (Day 0), and injected into tumor tissues of tumor-bearing mice at 5 ⁇ 10 5 cells/mouse. The remaining PBMCs were stopped and cultured, and 5 x 10 6 cells/mouse were intraperitoneally injected into tumor-bearing mice on day 7, and the 0th day was repeated on days 11, 14, and 17.
  • PD-1 antibody A and/or tail vein injection of bevacizumab were injected intraperitoneally, followed by two injections per week for a total of 6 doses. Tumor volume, animal body weight were monitored twice a week and data were recorded. At the end of the experiment, the animals were euthanized, the tumors were stripped and the tumor weight was weighed.
  • V 1/2 ⁇ a ⁇ b 2 where a and b represent length and width, respectively.
  • T/C(%) (TT 0 )/(CC 0 ) ⁇ 100, where T and C are the tumor volume of the treatment group and the control group at the end of the experiment; T 0 and C 0 are the beginning of the experiment. Tumor volume.
  • TGI (%) 1 - T / C (%).
  • the tumor weight in vitro was consistent with the trend of tumor volume.
  • the tumor weight of bevacizumab+PD-1 antibody A combination group and bevacizumab alone group was significantly lower than that of vehicle control group, and there were statistics. Learning differences (P ⁇ 0.001).
  • There was no significant difference in tumor weight between the bevacizumab+PD-1 antibody A combination group and the bevacizumab monotherapy group (p 0.0779), but the tumor weights in the two groups were ⁇ 0.5g.
  • 67% (6/9) vs. 11% (1/9) the advantages of the combined group can also be seen ( Figure 2 and Figure 3).
  • mice were well tolerated by bevacizumab and PD-1 antibody A alone or in combination, and the body weight increased steadily throughout the administration, only the vehicle control group and the PD-1 antibody group A.
  • the slight decrease in body weight at the last measurement may be due to the late growth of human malignant glioma U-87MG under the skin of mice, resulting in a decrease in the body of the mouse and no significant drug-induced weight loss (Figure 4).
  • D0 first administration time
  • a actual number (number of groups); BIW: twice a week;
  • I.P. intraperitoneal injection: I.V.: intravenous injection
  • Bevacizumab + PD-1 antibody A combination (3mg/kg, IV+IP, BIW ⁇ 6) significantly inhibited the growth of subcutaneous xenografts in human malignant glioma U-87MG mice (TGI 78.71%). And the tumor inhibition effect is better than +PD-1 antibody A single drug group (3mg/kg, IP, BIW ⁇ 6) and bevacizumab single drug group (3mg/kg, IV, BIW ⁇ 6), small tumor burden Rats are well tolerated by the above drugs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une utilisation d'un anticorps PD-1 combiné à un ligand VEGF ou à un inhibiteur du récepteur VEGF dans la préparation d'un médicament pour le traitement d'une tumeur.
PCT/CN2018/089763 2017-06-05 2018-06-04 Utilisation d'un anticorps pd-1 combiné avec un ligand vegf ou un inhibiteur du récepteur vegf dans la préparation d'un médicament pour le traitement d'une tumeur WO2018223923A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201880004442.XA CN109963592B (zh) 2017-06-05 2018-06-04 Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710412282 2017-06-05
CN201710412282.X 2017-06-05

Publications (1)

Publication Number Publication Date
WO2018223923A1 true WO2018223923A1 (fr) 2018-12-13

Family

ID=64566072

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/089763 WO2018223923A1 (fr) 2017-06-05 2018-06-04 Utilisation d'un anticorps pd-1 combiné avec un ligand vegf ou un inhibiteur du récepteur vegf dans la préparation d'un médicament pour le traitement d'une tumeur

Country Status (3)

Country Link
CN (1) CN109963592B (fr)
TW (1) TW201902514A (fr)
WO (1) WO2018223923A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021047623A1 (fr) * 2019-09-11 2021-03-18 Beigene, Ltd. Traitement du cancer à l'aide d'une combinaison comprenant un inhibiteur multicible de tyrosine kinase et un inhibiteur de point de contrôle immunitaire
WO2021104302A1 (fr) * 2019-11-25 2021-06-03 中山康方生物医药有限公司 Anticorps bispécifique anti-pd-1-anti-vegfa, composition pharmaceutique et leur utilisation
WO2021142237A1 (fr) * 2020-01-10 2021-07-15 Clovis Oncology, Inc. Procédés d'administration de lucitanib et de combinaisons de ce composé
CN113144189A (zh) * 2021-03-11 2021-07-23 江苏先声药业有限公司 Vegf抗体与免疫检查点抑制剂的联用
WO2021228069A1 (fr) * 2020-05-12 2021-11-18 信达生物制药(苏州)有限公司 Utilisation d'une combinaison d'anticorps anti-vegf et d'anticorps anti-pd-1 pour prévenir ou traiter une maladie
WO2022052874A1 (fr) * 2020-09-09 2022-03-17 深圳微芯生物科技股份有限公司 Utilisation de chiauranib en combinaison avec un inhibiteur de point de contrôle immunitaire en thérapie antitumorale

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115381831A (zh) * 2021-05-25 2022-11-25 成都中医药大学 一种预防和/或治疗癌症的药物组合物及其制备方法和用途
CN114931634B (zh) * 2022-03-18 2023-03-17 广州达博生物制品有限公司 E10a与pd1单抗对肿瘤的联合治疗方法和制药用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104271601A (zh) * 2012-05-31 2015-01-07 霍夫曼-拉罗奇有限公司 使用pd-1轴结合拮抗剂和vegf拮抗剂治疗癌症的方法
WO2015085847A1 (fr) * 2013-12-12 2015-06-18 上海恒瑞医药有限公司 Anticorps anti-pd-1, son fragment de liaison à l'antigène, et son application médicale
CN105175545A (zh) * 2015-10-20 2015-12-23 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd-1双功能抗体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016170039A1 (fr) * 2015-04-23 2016-10-27 F. Hoffmann-La Roche Ag Polythérapie d'anticorps se liant à l'angiopoïétine 2 avec un anticorps se liant au polypeptide de mort programmée 1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104271601A (zh) * 2012-05-31 2015-01-07 霍夫曼-拉罗奇有限公司 使用pd-1轴结合拮抗剂和vegf拮抗剂治疗癌症的方法
WO2015085847A1 (fr) * 2013-12-12 2015-06-18 上海恒瑞医药有限公司 Anticorps anti-pd-1, son fragment de liaison à l'antigène, et son application médicale
CN105175545A (zh) * 2015-10-20 2015-12-23 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd-1双功能抗体及其应用

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021047623A1 (fr) * 2019-09-11 2021-03-18 Beigene, Ltd. Traitement du cancer à l'aide d'une combinaison comprenant un inhibiteur multicible de tyrosine kinase et un inhibiteur de point de contrôle immunitaire
WO2021104302A1 (fr) * 2019-11-25 2021-06-03 中山康方生物医药有限公司 Anticorps bispécifique anti-pd-1-anti-vegfa, composition pharmaceutique et leur utilisation
WO2021142237A1 (fr) * 2020-01-10 2021-07-15 Clovis Oncology, Inc. Procédés d'administration de lucitanib et de combinaisons de ce composé
WO2021228069A1 (fr) * 2020-05-12 2021-11-18 信达生物制药(苏州)有限公司 Utilisation d'une combinaison d'anticorps anti-vegf et d'anticorps anti-pd-1 pour prévenir ou traiter une maladie
WO2022052874A1 (fr) * 2020-09-09 2022-03-17 深圳微芯生物科技股份有限公司 Utilisation de chiauranib en combinaison avec un inhibiteur de point de contrôle immunitaire en thérapie antitumorale
CN113144189A (zh) * 2021-03-11 2021-07-23 江苏先声药业有限公司 Vegf抗体与免疫检查点抑制剂的联用
CN113144189B (zh) * 2021-03-11 2022-07-12 山东先声生物制药有限公司 Vegf抗体与免疫检查点抑制剂的联用

Also Published As

Publication number Publication date
TW201902514A (zh) 2019-01-16
CN109963592B (zh) 2022-11-22
CN109963592A (zh) 2019-07-02

Similar Documents

Publication Publication Date Title
WO2018223923A1 (fr) Utilisation d'un anticorps pd-1 combiné avec un ligand vegf ou un inhibiteur du récepteur vegf dans la préparation d'un médicament pour le traitement d'une tumeur
US20240092902A1 (en) Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
CN109893654B (zh) Vegfr抑制剂治疗肿瘤的方法
AU2024202552A1 (en) Neutralization of inhibitory pathways in lymphocytes
JP2016506388A (ja) 抗ｃｄ３８抗体及びレナリドマイドを含む組成物
WO2018072743A1 (fr) Utilisation d'un anticorps anti-pd-1 conjugué à un inhibiteur de l'ido dans la préparation d'un médicament antitumoral
JP2021130668A (ja) 多発性骨髄腫（ｍｍ）の処置
CN110382532A (zh) 抗g-csf抗体及其用途
AU2016317378B2 (en) Agent for enhancing immunity to cancer by using Allergin-1 antagonist
JP7460608B2 (ja) 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法
US20210277135A1 (en) Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
TW202034925A (zh) Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途
KR20240038769A (ko) 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법
CN109663130A (zh) Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途
KR20200010472A (ko) 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임
WO2020049534A1 (fr) Agoniste de sting et polythérapie correspondante pour le traitement du cancer
JP3973360B2 (ja) 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子
CN112439060B (zh) Pd-l1免疫疗法的新用途
EP3164154A1 (fr) Polythérapie
TW201922292A (zh) 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途
CN110526972A (zh) 一种抗cd47抗体在制备治疗淋巴瘤的药物中的用途
EP3896089A1 (fr) Utilisation d'un anticorps pd-l1 d'articulation complexe de la protéine il-15 pour le traitement de maladies tumorales
JP2019505516A (ja) インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
WO2023051674A1 (fr) Anticorps anti-cd47 pour le traitement combiné d'une tumeur du sang
CN115957321A (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18812734

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18812734

Country of ref document: EP

Kind code of ref document: A1